CORMEDIX INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
CORMEDIX INC. (CRMD) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $143.43 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-05-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-05-29
- CORMEDIX INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2013-06-30 was $0.00.
- CORMEDIX INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2013-03-31 was $0.00.
- CORMEDIX INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was $143.43K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|
| 2018-12-31 | $143.43K 10-K · filed 2019-05-29 | ||
| 2013-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2014-03-04 | $0.00 10-Q/A · filed 2014-03-04 | |
| 2013-03-31 | $0.00 10-Q/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |